SCHEMBL15968872

SCHEMBL15968872

Nc1ccc(OCc2ccccc2)c(F)c1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 7/20 0.48
LTA4H P09960 1/20 0.46
MAPK14 Q16539 1/20 0.46
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
HTR1A P08908 2/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
APP P05067 1/20 0.42
DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34472968 0.86 KDM1A (0.50) KDM1ALTA4HMAPK14MAPTL3MBTL1
SCHEMBL31426395 0.82 KDM1A (0.47) KDM1ALTA4HMAPK14MAPTL3MBTL1
SCHEMBL8316680 0.82 MAOB (0.55) KDM1ALTA4HMAPK14MAPTL3MBTL1
SCHEMBL24819317 0.80 MAPT (0.61) LTA4HMAPK14MAPTL3MBTL1MAOA
SCHEMBL2479031 0.80 KDM1A (0.44) KDM1AMAPK14MAPTL3MBTL1MAPK1
SCHEMBL31166800 0.80 KDM1A (0.44) KDM1AMAPTL3MBTL1MAOBMAPK1
SCHEMBL30264760 0.79 KDM1A (0.50) KDM1ALTA4HMAPK14MAPTL3MBTL1
SCHEMBL16010603 0.76 SMPD1 (0.46) KDM1AMAPTL3MBTL1MAPK1TDP1
SCHEMBL31114193 0.76 MAPT (0.48) KDM1AMAPTL3MBTL1MAOAMAOB
SCHEMBL31114134 0.76 MAOB (0.55) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 US disclosed
EP-2772485-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-09-03 EP disclosed
US-20140243310-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 US disclosed
CN-103998432-A Bicyclic compounds TAKEDA PHARMACEUTICAL 2014-08-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243310-A1 BICYCLIC COMPOUND BICRA, NR3C2, CYP11B2 KDM1A 1508/4885LTA4H 2920/4885MAPK14 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.